Anti-Human EPCAM Recombinant Antibody (Adecatumumab) (CAT#: TAB-106)

Figure 1 Example of FACS binding analysis for ING-1 binding to transfected CHO cells.

FACS histograms are shown with eight CHO cell transfectants.

Münz, M., Murr, A., Kvesic, M., Rau, D., Mangold, S., Pflanz, S., ... & Rüttinger, D. (2010). Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer cell international, 10(1), 44.

Figure 2 CDC activity of five clinically tested anti-EpCAM monoclonal antibodies.

Human serum (10%) was added to cultures of KATO III gastric carcinoma cells and CDC after 45 min monitored by TDA released from lysed cells chelated with Europium and quantified by the fluorescence of the Europium-TDA chelates formed.

Münz, M., Murr, A., Kvesic, M., Rau, D., Mangold, S., Pflanz, S., ... & Rüttinger, D. (2010). Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer cell international, 10(1), 44.

Figure 3 The effect of adecatumumab on proliferation of breast cancer cell line and MCF-7 and normal breast epithelia line MCF10A.

The respective cell lines were seeded at 104 cells and cell numbers determined daily for three days. A human IgG1 isotype mAb and a blank served as controls.

Münz, M., Murr, A., Kvesic, M., Rau, D., Mangold, S., Pflanz, S., ... & Rüttinger, D. (2010). Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer cell international, 10(1), 44.

Figure 4 EpCAM expression by immunohistochemistry on primary/metastatic USPC versus normal endometrial tissue

A representative primary USPC showing strong (3+) EpCAM expression by immunohistochemistry.

El-Sahwi, K., Bellone, S., Cocco, E., Casagrande, F., Bellone, M., Abu-Khalaf, M., ... & Silasi, D. A. (2010). Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). Molecular cancer therapeutics, 9(1), 57-66.

Figure 5 Dose titration cytotoxicity experiments using MT201 against USPC ARK-5.

ADCC was found to plateau at a dose of 5 to 10 μg/mL in multiple experiments.

El-Sahwi, K., Bellone, S., Cocco, E., Casagrande, F., Bellone, M., Abu-Khalaf, M., ... & Silasi, D. A. (2010). Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). Molecular cancer therapeutics, 9(1), 57-66.

Figure 1 Anti-Human EPCAM Antibody (TAB-106) in ELISA

ELISA analysis of TAB-106 was performed with Human EpCAM Protein, His Tag.
The secondary antibody: HRP-Anti-Human IgG (H+L)

Figure 2 Anti-Human EPCAM Antibody (TAB-106) in WB

Western blot analysis of TAB-106 was performed with Human EpCAM Protein, His Tag.
TAB-106 incubation concentration: 2ng/μL.
The secondary antibody: HRP-Anti-Human IgG (H+L)
Lane 1: Reducing antigen (1μg)

Figure 3 Anti-Human EPCAM Antibody (TAB-106) in DB

Dot blot analysis of TAB-106 was performed with Human EpCAM Protein, His Tag.
TAB-106 incubation concentration: 2ng/μL.
NC: Negative control PC: Positive control